Australia’s first and only clinical and commercial-scale viral vector Contract Development and Manufacturing Organisation (CDMO), has officially opened in Sydney. This milestone marks a major step forward in strengthening Australia’s sovereign capabilities in advanced biomanufacturing.
Located within the Westmead Health and Innovation Precinct, the largest health, education, research, and innovation precinct in the country, VVMF is backed by a $134.5 million investment from the New South Wales (NSW) Government. The facility supports both state and national priorities to grow high-value jobs, boost exports, and attract international investment into NSW and Australia.
VVMF will deliver GMP-grade lentiviral (LV) and adeno-associated viral (AAV) vectors, supporting the development of transformative gene and cell therapies.
Services include:
Prof. Ian Alexander, Paediatrician and Chief Medical Officer, and Prof. Leszek Lisowski, vectrologist and Chief Technology Officer, are the founding scientists for the business, bringing deep scientific and clinical expertise from concept to clinic.
